candesartan cilexetil has been researched along with 8-hydroxy-2'-deoxyguanosine in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujita, A; Morito, N; Ojima, M; Okamura, M; Shimohata, H; Takahashi, S; Yamagata, K; Yoh, K | 1 |
1 other study(ies) available for candesartan cilexetil and 8-hydroxy-2'-deoxyguanosine
| Article | Year |
|---|---|
A novel diabetes mellitus mouse model, MAFA-deficient and beta cell-specific MAFK-overexpressing hybrid transgenic mice, developed severe diabetic nephropathy and improved with TCV-116 (candesartan cilexetil) treatment.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Deoxyguanosine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Humans; Kidney; Maf Transcription Factors, Large; MafK Transcription Factor; Male; Mice; Mice, Transgenic; Nephrectomy; Tetrazoles | 2012 |